Business Context and Reporting Period
This Form 8-K reports on the 2016 Annual Meeting of Stockholders held by Aquinox Pharmaceuticals, Inc. on May 9, 2016. The meeting took place at the offices of Cooley LLP in Seattle, Washington. Note: The input metadata references "Neurogene Inc.," but the filing text explicitly identifies the registrant as Aquinox Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals. The certified results are as follows:
- Proposal 1: Election of Class II Directors
- Daniel Levitt: 12,100,247 votes For; 8,212 votes Withheld; 2,485,901 Broker Non-Votes.
- Gary Bridger: 12,099,376 votes For; 9,083 votes Withheld; 2,485,901 Broker Non-Votes.
- Both nominees were elected to serve until the 2019 Annual Meeting.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the selection of Deloitte LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016.
- Votes For: 14,518,153
- Votes Against: 4,619
- Abstentions: 71,588
- Broker Non-Votes: None reported.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the submission of matters to a vote of security holders.
Important Facts for Investors to Verify
- Confirm the identity of the registrant (Aquinox Pharmaceuticals, Inc.) versus the metadata label (Neurogene Inc.).
- Verify the high volume of broker non-votes (approx. 2.48 million) on the director election, which may indicate significant institutional holdings where brokers lacked discretionary voting power.
- Review the definitive proxy statement (Schedule 14A filed March 25, 2016) for detailed biographies of the elected directors and the rationale for the auditor selection.